ADVANCE (Accelerate the Development of Vaccines and New Technologies to Combat the AIDS Epidemic), funded by a cooperative agreement through 2026 with the U.S. Agency for International Development (USAID) through the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR), aims to end HIV in partnership with Africa. Building on IAVI’s long-term partnership with USAID, ADVANCE partners include a network of African and Indian clinical research centers and the Human Immunology Laboratory at the Imperial College London.

ADVANCE is cultivating a core group of researchers and scientists in African institutions, to participate in the global effort to identify, evaluate, and implement HIV vaccines and biomedical prevention products in the fight against HIV. Together with its partners, IAVI provides research and technical assistance in implementing clinical trials, helps build capacity in transfer of technology, and leverages partnerships to build lasting vaccine research and development capacity on the continent. With ADVANCE, the results of community epidemiology studies can be applied to advance the development of an effective HIV vaccine or other biomedical prevention tools.

ADVANCE has four areas of focus:ADVANCE weave

  1. Create a Better Understanding of Communities and Cohorts by expanding the IAVI-partner clinical research network, creating an African-led, multi-stakeholder platform, which engages communities and investigates cohorts using the latest scientific technologies to inform vaccine discovery and development.
  2. Test Innovative Vaccines in Clinical Trials through ADVANCE’s End-to-End platform, partnering with global stakeholders to accelerate the development of an HIV vaccine candidate portfolio for the field.
  3. Engage in Africa-Centered Science by expanding the scope of Vaccine Immunology Science and Technology for Africa (VISTA), pairing leading global institutions with CORE, to transfer next-generation technologies to Africa, including sequencing-based antibody repertoire analyses, impact of microbiome on host immune responses, and bioinformatics technologies.
  4. Build Sustainable Capacity in Africa by transferring leadership of ADVANCE to leading African scientists, and investing in the next generation of researchers in multidisciplinary fields related to HIV prevention.

 

Read more about the ADVANCE partnership
Contributing to HIV Vaccine Research in Africa: USAID-Funded Science Capacity Building Partnership with IAVI